Techshot and nScrypt to launch 3D BioFabrication Facility in space

The3D BioFabrication Facility(BFF) bioprinter fromnScrypt, a Florida-based 3D printing system manufacturer, and spaceflight equipment developerTechshotis set to launch on theInternational Space Station(ISS) next month.

Said to be the first 3D printer capable of manufacturing human tissue in microgravity conditions, the BFF will be launched aboard theSpaceXCRS-18 cargo mission fromFlorida’sCape Canaveral Air Force Station. The partners hope that 3D bioprinting in space will be capable of producing self-supporting tissues that could lead to the development of therapeutic treatments.

“The concept of developing tissue or an organ in space with a 3D bioprinter has been with us for years,” saidJohn Vellinger, President and CEO of Techshot.

“From the technological and biological perspectives, making it real has been a painstaking process of experiments and testing. To see this coming together is an amazing thing for the team, as well as for all of medical science.”

Extraterrestrial 3D bioprinting

Based in Orlando, Florida,nScrypt是失去Sciperio公司which, under aDARPAcontract, developed an award-winning bioprinter in 2003. Techshot, on the other hand, is located in Greenville, Indiana, and has almost three decades of experience in the development of spaceflight equipment.

Vellinger’s first project to earn its place on a NASA mission was a KFC-sponsored payload intended to study how microgravity in space affects the growth of chicken embryos. In 2016, with help from bio-ink startup, Bioficial Organs, the companies were able to successfully3D print cardiac and vascular structures in zero gravity.

Last year, the following phase of a NASA sponsored mission to3D print human organs and tissues in spacewas announced to be launched in February 2019. Now, the quest of manufacturing hearts and other organs via a 3D bioprinter is continuing in July. This ultimately aims to reduce the current shortage of donor organs worldwide.

Space-made cell structures

During the companies years of research, it was found that 3D bioprinted soft, easily flowing biomaterials (i.e, human tissue) collapse under their own weight. However, these same materials are able to maintain their shapes when produced in the microgravity environment of space.

Thus, these structures, which will consist of blood vessels and muscle, will be 3D bioprinted in space and placed in a cell-culturing system that strengthens them over time. This will permit them to become viable, self-supporting tissues that will remain solid once back on Earth.